Back to today’s briefing

Story perspectives

FDA Approves Device to Detect Early Alzheimer’s Changes

5/25/2025

45 11

Summary

Oxford Innovations Advance

Oxford Brain Diagnostics has achieved FDA designation for a groundbreaking device that detects early neurodegenerative changes, paving the way for more effective Alzheimer’s treatments. In tandem, researchers have created a nanomaterial that may halt toxic protein buildup, offering hope for slowing disease progression. Together, these advancements are crucial as dementia cases surge worldwide.

Summary

Creatine Boosts Cognition

New research indicates that creatine monohydrate could enhance cognitive function in Alzheimer's patients. A pilot trial revealed promising results, with participants showing improved creatine levels in both blood and brain, linked to better cognitive performance. Yet, experts urge caution, recommending further studies and consultation with a neurologist before considering it as a treatment option.

1 of 2

Oxford Innovations Advance

Oxford Brain Diagnostics has achieved FDA designation for a groundbreaking device that detects early neurodegenerative changes, paving the way for more effective Alzheimer’s treatments. In tandem, researchers have created a nanomaterial that may halt toxic protein buildup, offering hope for slowing disease progression. Together, these advancements are crucial as dementia cases surge worldwide.

1 / 2